May 4, 2017
Date: May 4, 2017
Duration: 20 Min
This webcast features: James Brady, PhD, VP of Technical Applications and Customer Support, MaxCyte, Inc.
Moving bispecific and complex protein therapeutics from the bench to the clinic requires a scalable process that is consistent and reproducible while delivering a biologically active product. MaxCyte’s delivery platform is a high performance, electroporation-based technology that can rapidly generate milligram to gram quantities of protein in the cell line of choice.
You will learn:
How to express quality bi-specific antibodies, bi-specific T cell engaging (BITE) molecules, tribodies, and full IgGs in CHO cells
The importance of analyzing protein quality and glycosylation patterns to understand how transiently produced proteins mimic product qualities of stably produced proteins
About efficiently producing other difficult macromolecules, including viral vectors and multi-subunit drug targets, such as ion channels
How transient transfection using MaxCyte’s Flow Electroporation™ can delay or eliminate stable cell line generation while maintaining the integrity of candidate selection during biotherapeutic development
You May Also Like
